Kornimate/medical-research-clean huggingface dataset:
large-scale implementation of a decision aid about colorectal cancer screening

Conditions: Colorectal Cancer Screening

Summary: the goal of the project is to improve shared decision making and increase uptake of colorectal cancer (crc) screening by facilitating the implementation of a decision aid about crc and screening options in two healthcare systems in indiana.

this implementation project is putting a shared decision making approach into routine practice to help patients make informed decisions about colorectal cancer(crc) screening. regular screening is recommended for adults ages 45 - 75 years old, and there are multiple approved tests for individuals at average risk for colorectal cancer. a video-based decision aid about crc screening was developed and tested in a previous study by the project team. the study showed that viewing the decision aid had positive effects on measures directly related to shared decision making (knowledge, decision conflict) as well as intent to undergo crc screening. the project team is working with two healthcare systems to provide patients who are eligible for crc screening access to the decision aid, training staff and clinicians how to use the decision aid to support shared decision making for crc screening, working with healthcare system leaders to support the staff and clinicians, and providing support for the ongoing use of the decision aid.

Eligibility criteria:
inclusion criteria: * healthcare system participants will be eligible if they are employed by one of the project team's partner healthcare systems * patient participants will be eligible if they are considered due for colorectal cancer screening by the healthcare systems' criteria. exclusion criteria: patient participants will be excluded if they: * are not between ages of 45 - 75 years old * self-report that they no longer receive primary care at either of the project team's partner healthcare systems * self-report that they are not due for colorectal cancer screening (had colonoscopy within the past 10 years, sigmoidoscopy in the last 5 years, fit in the past year, or cologuard in the past 3 years) * are unable to speak or read english or spanish

Keywords: decision aid implementation colorectal cancer shared decision making electronic health record
the effect of tafamidis for the transthyretin amyloid polyneuropathy patients with v30m or non-v30m transthyretin

Conditions: Transthyretin Familial Amyloid Polyneuropathy

Summary: tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.


Eligibility criteria:
inclusion criteria: * transthyretin amyloid polyneuropathy with v30m or non-v30m transthyretin mutation. * subject had amyloid documented by biopsy in accordance with institutional site standard of care. exclusion criteria: * primary amyloidosis and secondary amyloidosis. * history of liver transplant.
primary angioplasty for stemi during covid-19 pandemic (isacs-stemi covid-19) registry

Conditions: ST Elevated Myocardial Infarction Undergoing Mechanical Reperfusion

Summary: the isacs stemi covid-19 has been established in response to the emerging outbreak of covid-19 to provide a european overview to estimate the real impact of covid-19 pandemic on treatment and outcome of stemi by primary angioplasty, and to identify any potential category of patients at risk for delay to treatment or no presentation.

this is a retrospective multicenter registry including at least 40 european primary pci centers with \> 120 primary pci/year (with expected average \> 10/month), with the case load of stemi not expected to be affected by a potential planned reorganization of the stemi network. the inclusion period will be of 2 months (from march 1st until april 30th). the data will be compared with those retrospectively collected in the same time window of 2019. inclusion criteria: stemi treated by primary angioplasty. primary study outcome: number of stemi patients undergoing primary angioplasty. secondary study outcomes: ischemia time and the number of late presenters (\> 12 hours from symptoms onset); 3) door-to-balloon time and the number of patients with a dtb \> 30 minutes); 4) in-hospital mortality. data collection: data will be collected anonymized through a dedicated crf. each center will identify a local principal investigator. we will collect information on the study center, demographic, clinical, procedural data. furthermore, we will collect data on total ischemia time, door-to-balloon time, type of access to the emergency system, covid positivity, pci procedure, data on in-hospital mortality.

Eligibility criteria:
inclusion criteria: stemi patients undergoing mechanical reperfusion -
radiofrequency ablation and steroid versus steroid alone for relief of pain in patients with advanced knee and hip osteoarthritis

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip

Summary: the purpose of this trial is to determine if radiofrequency ablation plus steroid perineural injections at the knee or hip provide longer pain relief and better function to patients than the current standard of care, perineural steroid injections alone. this pilot study is a prospective two arm randomized trail, all participants will be recruited from the university of texas southwestern medical center (utsw) outpatient orthopedic clinic. 40 participants (20 hip and 20 knee oa) will be enrolled into the standard of care arm (treated with steroid injections alone) and 40 participants (20 hip and 20 knee oa) will be enrolled into the investigational arm (treatment with a combination of radiofrequency ablation (rfa) plus steroid injections) for a total of 80 enrolled participants. all subjects will complete a function and pain assessment at the time of injection and three additional time points: 2 weeks, 3 months, and 6 months post injection. this study will use the same knee function questionnaire and frequency currently used in clinic per standard of care. in addition, all participant's surgical history and prior injection history will be reviewed via the electronic medical record (emr).


Eligibility criteria:
inclusion criteria: (1 \& 2 or 3) 1. males or females age 18 to 100 years 2. osteoarthritis of the knee kellgren-lawrence grade 3-4 or 3. osteoarthritis of the hip tonnis grades 2 or higher exclusion criteria: 1. history of knee or hip replacement 2. history of intra-articular steroid injections within the past 6 weeks 3. active infection

Keywords: osteoarthritis perineural steroid injections radiofrequency ablation
reducing rate of falls in older people by means of vestibular rehabilitation (refovere study)

Conditions: Dizziness Chronic; Fall

Summary: the aim of this study is to evaluate and compare the effectiveness of vestibular rehabilitation developed using computerized dynamic posturography or a mobile posturographic system with vibrotactile stimulation, to improve the balance in older people and reduce the number of falls.

accidental falls, particularly in the elderly, are one of the most important socio-healthcare problems of ageing western societies. many factors condition and favour falls; one of them is old age, usually related to a decline in sensorial functions and worsening of balance vestibular rehabilitation has been shown to be effective to improve balance and reduce the number of falls in older people. previous studies have demonstrated that exercises in computerized dynamic posturography (cdp) are more effective than other vestibular rehabilitation strategies in this group of age. but cdp is very expensive and not widespread. it would be important to minimize cost of posturographic vestibular rehabilitation. this study compare vestibular rehabilitation with two different posturographic devices (cdp and mobile posturographic system with vibrotactile stimulation), in people over 65 years. additionally, we try to assess whether the reduction in the number of vestibular rehabilitation sessions (five) leads to an improvement in balance and in reducing the number of falls similar to those obtained with ten sessions.

Eligibility criteria:
inclusion criteria: persons with a high risk of falling shall meet at least two of the following requirements: * having fallen at least once in the last 12 months. * using more than 15 seconds or needing support in the tug test. * obtaining a mean cdp sot balance score of \< 68%. * having fallen at least once in the cdp sot. * a score in mobile posturography gsbdt \> 60 %. exclusion criteria: * cognitive decline or reduce cultural level that prevents the patient from understanding the assessment, vestibular rehabilitation exercises and granting informed consent. * organic conditions that prevent standing on two feet, necessary for assessment of balance and performance of vr exercises. * balance disorders caused by conditions other than age (neurologic, vestibular,....). * current treatment with drugs that potentially disturb balance.

Keywords: vestibular rehabilitation falls in elderly computerized dynamic posturography mobile posturography
the diagnosis of beta-lactam hypersensitivity in thailand

Conditions: Penicillin Allergy; Aminopenicillin Allergy; Beta Lactam Adverse Reaction

Summary: the true prevalence of drug allergy in patients with a history of beta-lactam hypersensitivity will be determined by using commercially available standard skin test reagents and the diagnostic agents available in thailand. we hypothesize that only minority of patients with such a history are truly allergic.

patients with a history of beta-lactam hypersensitivity will be evaluated by the standard skin test reagents (major and minor determinants of penicillin, amoxicillin, and clavulanic if applicable), and intravenous forms of beta-lactam antibiotics . diagnostic values of the measurement of specific immunoglobulin e to penicillin/aminopenicillin and skin test reagents currently available in thailand will be comparatively analyzed with the standard skin test reagents. the measurement of drug-induced interferon-gamma releasing cells will be measured in patients with a history of non-immediate reaction.

Eligibility criteria:
inclusion criteria: * patients with a history of beta-lactam hypersensitivity exclusion criteria: * being pregnant * having serious medical illnesses

Keywords: drug allergy drug hypersensitivity beta-lactam allergy penicillin allergy adverse drug reaction
feasibility and practice characteristics of fns and gait robot

Conditions: Stroke

Summary: conventional therapies do not restore normal gait for many stroke survivors. the long-term goal of this work is to restore volitional lower limb motor control and gait following stroke. in our prior work, we demonstrated that it was feasible to provide a clinically operated, combined treatment of body weight supported treadmill training alone (bwstt) + functional neuromuscular stimulation (fns) using intramuscular (im) electrodes (fns-im). specific aims and hypothesis the purpose or specific aim of the study is to test the feasibility and gait training potential of combining the lokomat and fns-im for stroke survivors. given the feasibility of our clinically operated combination of bwstt + fns-im, we propose to test the feasibility of the combination of lokomat + fns-im. hypothesis i. it is feasible to utilize a clinically operated combination of lokomat + functional neuromuscular stimulation (fns) with intramuscular (im) electrodes (fns-im). treatment procedures. the subjects will be treated for three months, four sessions/week (for a total of 48 treatment visits). a given session will be 1 hrs, with the time divided into thirds as follows: 1) hr coordination exercise; 2) hr over ground gait training; and 3) hr lokomat gait training. fns-im will be used in all three aspects of the protocol, unless the subject is capable of volitionally executing a given movement or gait component. population. the subjects will be chronic stroke survivors (\>6 months after the stroke).


Eligibility criteria:
inclusion criteria: * greater than or equal to 6 months after stroke * 21 years or older * ability to follow 2 step commands * inability to move leg normally exclusion criteria: * pacemaker * progressive medical condition (i.e. parkinsons disease)

Keywords: cerebrovascular accident electrical stimulation gait training motor learning
eribulin mesylate combined with lobaplatin in the treatment of recurrent or metastatic triple-negative breast cancer

Conditions: Triple Negative Breast Cancer

Summary: a prospective phase ii study conducted at the cancer hospital chinese academy of medical sciences to compare the effectiveness of eribulin combined with lobaplatin in the treatment of recurrent or metastatic triple-negative breast cancer

this study is designed to be a prospective phase ii study conducted at the cancer hospital chinese academy of medical sciences. the target populations of this study are patients with recurrent or metastatic triple-negative breast cancer who received the therapy of eribulin combined with lobaplatin from july 1, 2020 to december 31, 2022. it is expected to enroll 40 subjects in this study. the subjects' data such as demographics and other baseline characteristics, medications, prognosis, will be collected, and statistical analysis of data will be conducted to compare the effectiveness outcome measures.

Eligibility criteria:
inclusion criteria: 1. female aged between 18 and 75 2. recurrence or metastasis of tnbc confirmed by histological or cytological methods, tnbc definitions of er, pr and her-2 are negative, if there is metastasis pathology, the histological pathology of metastasis shall prevail.er and pr negative were defined as er \< 10% positive and pr \< 10% positive. 3. disease progression after at least one prior systemic treatment and anthracycline and/or taxane use;note: for neoadjuvant/adjuvant therapy, recurrence or disease progression during treatment or within 6 months of discontinuation of treatment should be counted as first-line systemic treatment failure; 4. there should be at least one measurable lesion according to the efficacy evaluation criteria for solid tumors (recist version 1.1) exclusion criteria: 1. the number of previous treatment lines (including postoperative adjuvant therapy) \<2 lines 2. symptomatic central system metastases. patients with stable asymptomatic bms who have received brain radiation and who have at least one other evaluable target in addition to the bms can be enrolled (evaluable target should be at least 4 weeks away from the last radiotherapy). 3. new bisphosphonate or dinoselmer treatment for bone metastases was initiated within 28 days prior to study initiation.(subjects are permitted if they have already been treated with bisphosphonate or dinoselmer for at least 4 weeks of optimal stable administration prior to study initiation.)subjects already enrolled in this study may begin treatment with bisphosphonate or dinoselmer for bone metastases after the first post-treatment evaluation
ischemic preconditioning and type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: the aim of this study is to determine the impact of 7 days of daily ischemic preconditioning (ipc) on vascular function and insulin sensitivity in type 2 diabetes mellitus.

occlusion (cuff inflation to a pressure that reduces blood flow) using a blood pressure cuff on the upper arm for 5 mins followed by recovery (cuff deflation so blood flows normally gain), is known as ischemic preconditioning (ipc). an intervention consisting of 4 cycles of 5 min arm occlusion followed by 5 min periods of recovery on a daily basis can improve blood vessel function. this is a simple and easily applicable intervention that immediately improves the blood vessels capacity to deliver blood to an organ (e.g. heart or the muscle). however, it is currently unknown if a daily ipc can improve blood vessel function in patients with type 2 diabetes mellitus (t2dm) and if it will aid in improving blood glucose control. therefore, the purpose of this study is to investigate if daily ipc for 7 days can improve blood vessel function and blood glucose control in t2dm. this randomised control trial consists of 3 visits to liverpool john moores university; before intervention, immediately following intervention, and 8 days following the end of the intervention. participants will be trained to apply the ipc device and then perform it at home daily for 7 days.

Eligibility criteria:
inclusion criteria: * able to provide written consent * males and females 18-75 years * diagnosis of t2dm * currently treated with diet or of metformin exclusion criteria: * type 1 diabetes mellitus * previous myocardial infarction, stroke (including tia) or thrombosis * diagnosed with congestive heart failure * unable to enroll for the duration of the study * pregnancy or lactation period * currently treated with sulponylureas (ddpiv inhibitors/pioglitazone or insulin) or glucagon like peptide1
exploring 8-iso prostaglandin f2α and adenosine deaminase levels in periodontal health and disease

Conditions: Periodontal Diseases

Summary: this study aims to assess the diagnostic potential of gingival crevicular fluid (gcf) biomarkers, specifically 8-iso prostaglandin f2α (8-iso-pgf2α) and adenosine deaminase (ada), in evaluating periodontal health and disease conditions.

conducted as a single-blind, cross-sectional investigation, this study comprised 26 individuals categorized as periodontally healthy, 27 with gingivitis, and 27 diagnosed with periodontitis. the participant pool included individuals with various periodontal concerns who were referred to the department of periodontology clinic at kahramanmaraş sütçü i̇mam university. the classification of periodontal health, gingivitis, and chronic periodontitis adhered to the 2018 criteria outlined by the european federation of periodontology

Eligibility criteria:
inclusion criteria: * patients having more than 20 teeth, minimum age 18, maximum age 65 exclusion criteria: * patients with systemic disease, active smokers, pregnant women, individuals with a history of orthodontic treatment, or those who had undergone periodontal treatment, regardless of whether it was surgical or non-surgical (within the last one year),

Keywords: 8-isoprostane, adenosine deaminase, gcf
efficacy and safety of homeopathy for moderate depression (acute phase)

Conditions: Major Depression

Summary: to assess the two components of individualized homeopathic treatment for acute depression, i.e., to investigate the specific effect of individualized q-potencies versus placebo and to investigate the effect of different approaches to the homeopathic case history taking(defined in this study as case history taking type i and ii).

homeopathy is often sought by patients with depression. in classical homeopathy, the treatment consists of two main elements: the taking of the case history and the prescription of an individually selected homeopathic remedy. homeopathic medicines are produced through sequential, agitated dilutions. a q-potency is prepared by grinding the raw material, followed by a process of consecutive 1:50.000 agitated dilutions. previous data suggest that individualized homeopathic q-potencies were non inferior to the antidepressant fluoxetine in a sample of patients with moderate to severe major depression. the question remains whether individualized homeopathic q-potencies have a specific therapeutical effect in acute depression as this has not yet been investigated.

Eligibility criteria:
inclusion criteria: * diagnosis of major depression by a psychiatrist, * patients must not be currently taking antidepressants or anxiolytic drugs (with the exception of lorazepam as rescue medication, maximal dose 1.5 mg/day) * capability and willingness to give informed consent and to comply with the study procedures will also be required exclusion criteria: * current mild episode of depression (ham-d \< 17) * current severe episode of depression (ham-d \> 24) * schizophrenia or other psychotic disorders * bipolar affective disorder * schizoaffective disorders * alcohol or other substance abuse * eating disorders * a clinically significant (diagnostic and statistical manual of mental disorders)-axis ii disorder * severe depression, which previously motivated a suicide attempt * a score of 4 or 5 in the columbia-suicide severity rating scale (c-ssrs)up to three months before screening; * a clinically significant acute or chronic disease that would hinder regular participation in the study * treatment with antipsychotics, antidepressants, sedatives/hypnotics or mood stabilizers four weeks prior to the screening * complementary or alternative treatment simultaneously to the study (for example, acupuncture, phytotherapy, etc.) * homeopathic treatment eight weeks prior to study entry * psychotherapy * simultaneous participation in another clinical trial (the last participation in a previous clinical trial must be completed at least three months prior to screening) * concomitant pregnancy or breastfeeding * patients who are assumed to have a linguistic, intellectual or any other reason for not understanding the meaning of the clinical trial and for not complying with the necessary study procedures * persons who have been institutionalized by a court order * patients with an application for a pension

Keywords: depression homoeopathy
an international study to evaluate the real-world effectiveness and usage of alprolix in patients with haemophilia b

Conditions: Hemophilia B

Summary: alprolix (rfixfc) is a recombinant extended half-life coagulation factor product. the purpose of this non-interventional study is to describe the real-world usage and effectiveness of alprolix in the on-demand and prophylactic treatment of haemophilia b.


Eligibility criteria:
inclusion criteria: * have a diagnosis of haemophilia b * have started alprolix treatment prior to enrolment visit, or at enrolment prescribed treatment with alprolix irrespective of participation in the study * signed and dated informed consent provided by the patient, or the patients legally acceptable representative for patients under the legal age, before any study-related activities are undertaken. assent should be obtained from paediatric patients according to local regulations. exclusion criteria: * participation in an investigational medicinal product trial at enrolment visit

Keywords: blood coagulation disorder hematologic diseases coagulation protein disorder hemorrhagic disorder genetic diseases, inborn
extension study of mt-1303

Conditions: Relapsing-remitting Multiple Sclerosis

Summary: to evaluate the long-term safety and tolerability of mt-1303 in subjects with relapsing remitting multiple sclerosis (rrms).


Eligibility criteria:
inclusion criteria: * completion of the 24-week treatment period in mt-1303-e04 as per protocol * able to provide written informed consent and to comply with the requirements of the protocol * for males and females of reproductive potential, two methods of contraception must be used throughout the study and for 12 weeks after cessation of study medication. at least one of the methods of contraception must be a barrier method. exclusion criteria: * permanent discontinuation of study medication prior to the end of treatment (eot) visit in mt-1303-e04 * newly diagnosed diabetes mellitus during mt-1303-e04

Keywords: relapsing-remitting multiple sclerosis rrms
comparison between bladder dissection before and after uterine incision in cesarean section for morbidly adherent placenta

Conditions: Morbidly Adherent Placenta

Summary: comparison between bladder dissection at the beginning of cesarean section for morbidly adherent placenta and between delaying dissection until planning for cesarean hysterectomy


Eligibility criteria:
inclusion criteria: 1. women with bmi at or under 35 kg/m2. 2. women having previous two cesarean section or more. 3. women with gestational age more than 32 weeks with viable fetus. 4. women with any degree of placenta previa . 5. patient with morbidly adherent placenta on cesarean scar only. exclusion criteria: 1. patient who are haemodynamically unstable before skin incision. 2. patient with clinically evident intraamniotic infection. 3. patient with previous history of bladder injury .